Skip to main content

Table 2 Outcomes of antituberculosis and antiretroviral treatment

From: Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study

Outcomes of tuberculosis at completion of ATT

Outcome

Nevirapine group

Efavirenz group

P value

Ā 

nā€‰=ā€‰67

nā€‰=ā€‰68

Ā 

Successfully treated

50 (74.6%)

51 (75.0%)

0.26

Lost to follow up

06 (9.0%)

06 (8.8%)

Died

11 (16.4%)

09 (13.2%)

On ATT at end of study

00

02 (2.9%)

Outcomes of ART after 24 months

Outcome

Nevirapine group

Efavirenz group

P value

nā€‰=ā€‰67

nā€‰=ā€‰68

Mortality:

Ā Ā Ā 

Observed

13 (19.4%)

10 (14.7%)

0.46

(% Adjusted for type of TB)

19.1%

14.9%

0.50

ART failure:

19 (28.4%)

21 (30.9%)

0.75

Clinical failure

06 (9.0%)

06 (8.8%)

0.98

Immunological failure

06 (9.0%)

08 (11.8%)

0.58

Virological failure

10 (14.9%)

09 (13.2%)

0.94

Composite unfavourable outcome

30 (44.8%)

29 (42.6%)

0.98

(Death and/or ART failure)

  1. ATTā€‰Antituberculosis treatment, ARTā€‰Antiretroviral therapy.